NCT03929965Unknown不适用
Anlotinib in Advanced Solid Tumors With FGFR Alteration
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Objective Response Rate(ORR)
研究概览
简要总结
This clinical trial aims to evaluate the efficacy, safety of Anlotinib in advanced solid tumors with FGFR alteration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients should be histologically diagnosed with advanced solid tumors; Patients with FGFR mutation(including mutation, fusion, rearrangements ); Patients have measurable lesions; Patients are not available for targeted therapy or patients refuse to receive targeted therapy afer second-line treatment; Over 3 weeks after radiotherapy and the radiotherapy focus was not be measured; Age should be 18-25 years; Performance status should be 0-2; Life expectancy should be more than 12 weeks;
排除标准
- •Patients underwented major surgery or severe trauma within 4 weeks; Patients allergiced to experimental drugs; Patient ready to give birth or who is pregnant; Patients with brain metastases; Patients with chemotherapy contraindication; Patients could not tolerate chemotherapy; Patients have secondary primary tumor.
研究组 & 干预措施
advanced solid tumors with FGFR alteration
Experimental
干预措施: Anlotinib (Drug)
结局指标
主要结局
Objective Response Rate(ORR)
时间窗: up to 36 months
Evaluation of tumor burden based on RECIST criteria.
次要结局
未报告次要终点
研究者
Zhan Wang
Anlotinib in advanced solid tumors with FGFR alteration
Shanghai Changzheng Hospital
研究点 (1)
Loading locations...
相似试验
撤回
不适用
Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial CarcinomaEndometrial NeoplasmsNCT01888562Washington University School of Medicine
Unknown
2 期
Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With GefitinibEGFR Gene MutationNon-small Cell Lung CancerNCT04358562Second Affiliated Hospital of Nanchang University240
已完成
2 期
Anlotinib in Metastatic HER2 Negative Breast CancerBreast NeoplasmAntineoplastic AgentsAnlotinibNCT04002284Peng Yuan26
终止
2 期
Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790MAdvanced NSCLC Patients With T790MNCT03452592Allist Pharmaceuticals, Inc.220
终止
1 期
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsSquamous Cell Carcinoma of the Head and NeckPancreatic Ductal AdenocarcinomaNCT05983133Seagen, a wholly owned subsidiary of Pfizer68